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Abstract
Pancreatogenic diabetes mellitus is most commonly the result of chronic pancreatitis, but can also 
occur secondary to pancreatic cancer. The early identification of pancreatogenic diabetes and 
distinction from the more prevalent type 2 diabetes is clinically significant; however, currently 
there is no validated method to differentiate these diabetes subtypes. We describe a study, 
“Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC 
DiabeTes Secondary to Pancreatic Cancer and Chronic Pancreatitis: the DETECT study,” which 
seeks to address this knowledge gap. The DETECT study is a multicenter study that will examine 
differences in hormone and glucose excursions following a mixed meal test. The study will also 
create a biorepository that will be used to evaluate novel diagnostic biomarkers for differentiating 
these diabetes subtypes.
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INTRODUCTION
Diabetes mellitus (DM) secondary to an inherited or acquired disease of the exocrine 
pancreas is collectively termed pancreatogenic or type 3c diabetes mellitus (type 3c DM).1,2 
The most commonly recognized causes of pancreatogenic DM are chronic pancreatitis and 
pancreatic ductal adenocarcinoma (PDAC), accounting for approximately 80% and 10% of 
cases, respectively (Fig. 1).3 The lifetime prevalence of DM in chronic pancreatitis can reach 
up to 80%, with a point prevalence of 40%.4,5 The prevalence is dependent on both patient 
and disease-related factors, including age, body mass index, family history, duration of 
pancreatic disease, presence of exocrine insufficiency, and pancreatic surgery.4,5 The 
prevalence of DM in PDAC at the time of diagnosis is ~50%, importantly 75% of these 
patients are diagnosed with DM within 2 years prior to the diagnosis of cancer.6 The overall 
prevalence of pancreatogenic DM amongst those with diabetes ranges from 2 to 9%.3,7,8 
However, the true prevalence is difficult to determine due to the inability to differentiate it 
from the more prevalent type 2 DM (T2DM) and lack of validated diagnostic criteria. The 
primary purpose of the DETECT (Evaluation of a Mixed Meal Test for Diagnosis and 
Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic Cancer and Chronic 
Pancreatitis) study is to develop a method to distinguish the two aforementioned subtypes of 
pancreatogenic diabetes from T2DM.
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METABOLIC CHANGES OBSERVED IN PANCREATOGENIC DM
The pathophysiology of pancreatogenic DM is complex, as defects in insulin secretion, 
insulin action, and incretin secretion have been previously discussed.2,9 The clinical 
presentation is heterogenous, due to differences in the nature and severity of the underlying 
pancreatic diseases. A new subclassification of causes of pancreatogenic DM was recently 
proposed (Table 1) to better distinguish underlying causes.2 Considering the known (and 
suspected) differences in these subtypes of pancreatogenic DM, it is most appropriate to 
specifically refer to the exocrine pancreatic disease to avoid misinterpretations. For example, 
herein we refer to two different causes of pancreatogenic DM: 1. Chronic pancreatitis-
related diabetes mellitus (CP-DM), and 2. Pancreatic cancer-related diabetes mellitus 
(PDAC-DM). This nomenclature is consistent with the widely used designation of cystic 
fibrosis-related diabetes mellitus (CFRD).
The primary defect in pancreatogenic diabetes is relative or absolute insulin deficiency. Loss 
of insulin secretion is commonly accompanied by loss of other glucoregulatory islet 
hormones, including glucagon and pancreatic polypeptide (PP). This global failure of islet 
hormone release may be mediated by the action of activated pancreatic stellate cells,10 the 
effect of pro-inflammatory cytokines,11 or loss of pancreatic parenchyma. In diabetes that is 
a consequence of, and frequently a harbinger of, PDAC (i.e., PDAC-DM), insulin secretion 
is impaired due to what is thought to be a paraneoplastic phenomenon, potentially mediated 
by PDAC-derived exosomes.12 Pancreatic polypeptide deficiency might be a unique 
hallmark of pancreatogenic DM. Particularly in chronic pancreatitis, a deficiency of PP is 
often seen, and has been associated with reduced hepatic sensitivity to insulin.13, 14 
Administration of PP reverses hepatic insulin resistance in PP-deficient patients.15–17 In 
PDAC, impaired hepatic insulin sensitivity may be a consequence of the loss of PP secretion 
associated with tumor localized to the pancreatic head.18,19 The primary aim of the 
DETECT study is to determine whether a deficient PP response to mixed meal stimulation 
can distinguish pancreatogenic DM from T2DM.
While insulin deficiency is the core defect in pancreatogenic DM, several other 
abnormalities in glucose homeostasis are frequently observed. Insulin resistance has been 
documented in both chronic pancreatitis and PDAC.20–23 Alpha cell dysfunction 
(insufficient glucagon response to hypoglycemia and insufficient suppression by oral 
glucose) was recently found to be similar in subjects with T2DM and CP-DM.24 Whether 
the enteroinsular axis (meal-induced secretion of incretin hormones from the gut that 
stimulate beta-cell insulin secretion) is disturbed in pancreatogenic DM remains uncertain, 
given inconsistent results in studies of basal and stimulated incretin hormone levels in 
chronic pancreatitis with or without diabetes; this axis has not been well studied in PDAC-
DM.25–29 In individuals with chronic pancreatitis and impaired glucose tolerance or diabetes 
and exocrine insufficiency, administration of pancreatic enzyme supplementation boosted 
GLP-1 and GIP secretion, and consequently the insulin response to liquid meals.30,31 The 
DETECT study is also designed to evaluate insulin resistance, alpha-cell dysfunction and 
disturbed incretin hormone response in CP-DM and PDAC-DM.
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CLINICAL RELEVANCE OF PANCREATOGENIC DM
The clinical relevance of pancreatogenic DM differs according to the underlying pancreatic 
disease. For example, in CP-DM chronic hyperglycemia may lead to long-term 
complications similar to those observed in T2DM.32–34 Distinguishing pancreatogenic DM 
from T2DM impacts treatment given that patients with the former tend to have higher 
hemoglobin A1c and an earlier need for insulin.7 In the absence of clinical trials, treatment 
approaches for pancreatogenic DM have been extrapolated from management of type 1 DM 
(T1DM) and T2DM.2,9
In addition to the need to treat hyperglycemia and avoid long-term complications, the 
presence of pancreatogenic DM may present a unique opportunity for early diagnosis of 
PDAC. Importantly, studies have demonstrated a markedly increased risk for developing 
PDAC in those diagnosed with CP-DM.35,36 On the other hand, new onset diabetes occurs in 
up to 50% of patients with PDAC, with many more having glucose intolerance.37,38 The 
PDAC-DM diagnosis typically occurs from 6 months to three years before the PDAC is 
diagnosed, and roughly half of the patients with new-onset diabetes show improvement or 
resolution of hyperglycemia either following resection of the malignancy or treatment 
response to neoadjuvant chemotherapy.6,38–40 Thus, the development of hyperglycemia may 
represent the earliest “symptom” of PDAC, providing a potential window of opportunity for 
early detection. However, historical and clinical features do not clearly differentiate patients 
with PDAC-DM from patients with new-onset T2DM.41 Therefore, a key secondary purpose 
of the DETECT study is to provide a platform for evaluation of novel protein and peptide 
markers as indicators of new onset PDAC-DM compared to T2DM.
CURRENT DIAGNOSTIC APPROACH TO PANCREATOGENIC DM
In cases of antecedent chronic pancreatic disease, the subsequent development of diabetes is 
highly likely to be pancreatogenic.42 In contrast, in cases of new onset diabetes in the 
absence of known pancreatic disease, pancreatogenic DM is diagnosed clinically following 
exclusion of T1DM (ruled out by the absence of antibodies associated with T1DM)) and 
identification of a functional or imaging abnormalities associated with a pancreatic disease. 
Rickels et al suggested that the disparity of PP levels, which are elevated in T2DM and low 
in various subtypes of pancreatogenic DM, might confirm the presence of pancreatogenic 
DM.43 Low basal and nutrient-stimulated PP levels have been reported in CP-DM, 
pancreatic resection, cystic fibrosis, and PDAC-DM, all of these studies have been in small 
cohorts of patients and need to be further validated in the disease subgroups.9,18,44 The need 
for validated diagnostic criteria for pancreatogenic DM is urgent in order to advance clinical 
studies.
In 2013, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and 
the National Cancer Institute (NCI) sponsored a workshop in which many research needs 
were identified, including the need to differentiate pancreatogenic DM from T2DM.45 This 
workshop and the passage of the Recalcitrant Cancer Act by the US Congress in 2012 
provided the justification for the development of a program co-sponsored and jointly funded 
by the NIDDK and NCI that is now called the Consortium for the Study of Pancreatitis, 
Hart et al. Page 4
Pancreas. Author manuscript; available in PMC 2019 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Diabetes, and Pancreatic Cancer (CPDPC).46,47 The Type 3c (pancreatogenic) Diabetes 
Working Group was chartered soon after the organization of the CPDPC. The DETECT 
study is the primary study of this working group.
STUDY DESIGN
Hypotheses and Objectives
The general hypothesis underlying the DETECT study is that hormone and glucose 
excursions measured during a mixed meal test can distinguish patients with new onset 
PDAC-DM and/or CP-DM from patients with T2DM. For the purposes of this study, new 
onset diabetes is defined as diabetes that has developed within the preceding 36 months. Our 
primary objective is to test the hypothesis that the relative change in PP levels at 30 minutes 
following meal stimulation will be significantly lower (defined a priori as 20% lower) in the 
PDAC-DM and CP-DM groups compared to T2DM. Secondary objectives include 
additional comparisons across the same groups regarding insulin, glucagon, and incretin 
hormone responses.
Study Design Summary
Enrollment
The goal of the study is to recruit a total of 452 subjects with PDAC, chronic pancreatitis, 
and no structural pancreatic disease (Table 2) at 9 participating clinical centers. Control 
subjects will be considered to have “no structural pancreatic disease” in the absence of 
clinical, laboratory, and/or imaging data to support the diagnosis of a pancreatic disorder 
(i.e., chronic pancreatitis or PDAC). Eligible subjects will be approached through a variety 
of methods, including participation in other related clinical studies performed by the 
CPDPC.48,49
Mixed Meal Testing Protocol
To reduce confounding from medication use, the following medications will be held on the 
morning of the study visit: antihyperglycemic agents, pancreatic enzyme supplementation, 
and systemic anticholinergics. Subjects will be asked to consume a standard mixed meal 
consisting of 12 oz Boost® drink, chocolate flavor providing 360 calories, 15 g protein, 61.5 
g carbs, and 6 g fat. Blood samples will be collected at fasting baseline (−5 and 0 minutes), 
then 15, 30, 45, 60, 90, and 120 minutes following meal stimulation. Samples will be 
processed and stored according to a study-specific biospecimen standard operating 
procedures manual. The samples will be batch analyzed at a central laboratory to measure 
the analytes of interest, including PP, glucose, c-peptide, insulin, glucagon, GLP-1, and GIP 
levels. All subjects will complete a standardized questionnaire regarding personal medical 
and medication histories as well as family history.
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Eligibility Criteria
Inclusion Criteria
Subjects with PDAC, chronic pancreatitis, and no disease of the exocrine pancreas will be 
enrolled based on their diabetes status as illustrated in Table 2. Subjects must be ages ≥40 
and <85 years. The rationale for the age restriction is to concentrate the study population to 
an age distribution that overlaps with both PDAC and chronic pancreatitis.
Exclusion Criteria
Subjects using high dosages of insulin (total daily dose ≥0.5 unit/kg/day), long-acting 
antihyperglycemic agents, or other medications that would confound the study results will 
not be enrolled. Similarly, subjects with a prior pancreatic surgery (including total 
pancreatectomy, pancreaticoduodenectomy, distal pancreatectomy, pancreaticojejunostomy, 
enucleation, or Frey procedure), gastric surgery, or vagotomy are ineligible. Lastly, subjects 
with PDAC who have received previous treatment for pancreatic cancer, including 
chemotherapy or radiation, will be excluded.
Statistical Power Calculation
The priority for the test being studied is to rule out T2DM in patients who may have T2DM, 
PDAC-DM, or CP-DM; therefore, a high sensitivity is desirable. Fixing the sensitivity at 
90%, the mixed meal test is regarded as not useful if its specificity to distinguish new-onset 
T2DM from PDAC-DM or CP-DM is ≤25%. Based on preliminary data examining PP 
response for diagnosis of pancreatogenic DM (in subjects with new onset PDAC-DM and 
T2DM),19 when the sensitivity is 90%, the specificity is approximately 44%. If we assume 
that the true specificity for this study is 44% and the significance level of 5%, to achieve 
80% power, we need to enroll 136 subjects with new onset PDAC-DM, 136 subjects with 
new onset CP-DM, and 100 subjects with new onset T2DM (Table 2). A smaller number of 
subjects (10–20 per subgroup) will be enrolled to generate pilot data from the six subject 
sub-groups with either long-standing diabetes or no diabetes.
Statistical Plan
The Wilcoxon signed-rank test and t-test will be used to determine if there is a significant 
difference in the PP response (measured as the change of absolute and relative levels of PP 
compared to fasting, basal levels) at each time point (with the primary outcome at 30 
minutes). Intergroup analyses will be performed to compare the median (or mean) relative 
change in PP (%) from baseline to each time point, as well as the area under the curves 
(AUC), using the Kruskal-Wallis test and analysis of variance (ANOVA). Linear regression 
and mixed model will be conducted to further compare the changes in PP (%) from baseline 
between three new onset diabetes subgroups at each time point and across time points, while 
controlling potential confounders. Comparison of the groups based on insulin, glucagon, and 
incretin secretion responses will be executed using a similar statistical methodology.
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FUTURE IMPACT OF THE DETECT STUDY
The DETECT study is the first to comprehensively compare dynamic changes in beta-cell 
function, insulin resistance, and pancreatic and gut hormone levels using a standardized 
meal in a large cohort of subjects with T2DM, PDAC-DM, and CP-DM. These data will be 
useful to develop diagnostic criteria for pancreatogenic DM, refine our understanding and 
ongoing studies of CP-DM, and further examine the potential to screen for sporadic PDAC. 
The results will be used to propose diagnostic criteria for pancreatogenic DM for use in both 
future research studies and clinical practice. Such criteria are awaited to execute more 
rigorous epidemiologic studies to refine the estimates of the burden of pancreatogenic DM. 
Furthermore, the ability to diagnose pancreatogenic DM will guide management decisions 
and foster prospective studies to define the role of such testing in predicting the risk of DM 
and whether intervention(s) can help to delay its onset. Furthermore, data generated from the 
DETECT study will also allow ancillary comparisons within the cohort studies being 
performed within the CPDPC, particularly in chronic pancreatitis. Stratification of chronic 
pancreatitis subjects in Prospective Evaluation of Chronic Pancreatitis for Epidemiologic 
and Translational Studies (PROCEED) by the type of DM based on differential glucose and 
hormone responses will also be used to assess different patterns of risk for disease-related 
outcomes, including exocrine insufficiency, metabolic bone disease, and interval PDAC.49 
Finally, accurate discrimination of PDAC-DM from the much more prevalent T2DM 
amongst patients with undifferentiated diabetes would define a high-risk group in whom 
further screening studies would be feasible.
The DETECT study specimen collections are carefully planned to allow future evaluation of 
both baseline and meal-stimulated biomarkers. It is unclear if there are host-related 
biomarkers (such as genetic markers) that are distinct for pancreatogenic DM compared to 
T1DM and T2DM and what degree of heterogeneity exists within the various subtypes of 
pancreatogenic DM. For example, is pancreatogenic DM related to chronic pancreatitis 
different from the diabetes related to all PDAC, or to subsets of PDAC? We envision the 
current and future biomarker studies using high-throughput assays (including genomic, 
proteomic, and metabolomics approaches) from the DETECT study will provide similar 
insights to those that have occurred in other chronic diseases, including T2DM, to allow 
investigators to monitor, predict, and unravel mechanisms of disease pathogenesis.
In summary, the DETECT study is a large, multicenter clinical study that seeks to identify a 
simple clinical test to distinguish new onset PDAC-DM and CP-DM from the more common 
T2DM. The study will involve collection of biosamples prior to and following mixed meal 
stimulation to comprehensively assess different patterns of beta-cell function, insulin 
resistance, and pancreatic and gut hormone responses. These results will provide a strong 
foundation to support ongoing and future studies to further understand the underlying 
pathophysiology, diagnosis, and treatment of pancreatogenic DM.
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FIGURE 1. 
Prevalence and etiologies of pancreatogenic DM. A, Prevalence of pancreatogenic (Type 3c) 
DM in a cohort of 1868 subjects with diabetes. B, Proportion of different subtypes in the 
subset of subjects (n = 117) with pancreatogenic DM. Adapted with permission.3
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Table 1.
Proposed Subclassification of Pancreatogenic Diabetes According to Their Potential Mechanisms
Congenital or acquired complete absence of islets
    Pancreatic agenesis
    Pancreatectomy (total)
Acquired partial absence of functional islets
    Chronic pancreatitis*
    Pancreatectomy (partial)
    Severe acute pancreatitis
    Cystic fibrosis
    Hemochromatosis
Paraneoplastic
    Pancreatic ductal adenocarcinoma
Other
    Transient† hyperglycemia of acute pancreatitis
*
Includes tropical pancreatitis, which was previously referred to as fibrocalculous pancreatopathy.
†
Hyperglycemia secondary to acute pancreatitis may persist for weeks.
Adapted with permission.2
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Table 2.
DETECT Study Cohort Composition
Pancreatic Disease State Diabetes Status, n
New-onset Long-standing Non-diabetic
No Disease 100* 10* 10†
Chronic Pancreatitis 136 10 10
Pancreatic Cancer 136 20 20
*
Indicates subjects with T2DM.
†
Indicates healthy control subjects without diabetes.
Pancreas. Author manuscript; available in PMC 2019 November 01.
